William Goundry serves as a Principal Scientist in AstraZeneca's Early Chemical Development (ECD) group, where he plays a pivotal role in advancing innovative therapeutic modalities. With a strong foundation in Chemistry Manufacturing and Controls (CMC), William leads the clinical supply of drug substances for cutting-edge...
William Goundry serves as a Principal Scientist in AstraZeneca's Early Chemical Development (ECD) group, where he plays a pivotal role in advancing innovative therapeutic modalities. With a strong foundation in Chemistry Manufacturing and Controls (CMC), William leads the clinical supply of drug substances for cutting-edge New Modalities, including Antibody-drug Conjugates (ADCs), Antisense Oligonucleotides (ASOs), Oral Peptides, Inhaled Peptides, and Drug Conjugates, up to Phase 2b clinical trials. His expertise in organic synthesis and pharmaceutical development is complemented by his adeptness in process development, allowing him to streamline workflows and enhance efficiency in drug production.
William's leadership extends beyond technical proficiency; he is passionate about mentoring and coaching his team, fostering an environment where creativity and innovation thrive. His ability to communicate complex scientific concepts effectively ensures that all stakeholders are aligned and informed throughout the development process. He actively engages in external science collaborations, leveraging partnerships to drive advancements in drug delivery and formulation strategies.
Adept in statistics and outsourcing management, William employs a data-driven approach to problem-solving, ensuring that projects are not only scientifically sound but also strategically aligned with AstraZeneca's broader goals. His influential presence within the organization is marked by his commitment to personal development and team building, inspiring colleagues to reach their full potential while contributing to the development of novel therapies that address unmet medical needs. Through his work, William Goundry exemplifies the intersection of scientific innovation and effective leadership in the pharmaceutical industry.
